Azirkitug Biosimilar – Anti-CKR-L1 mAb – Research Grade from ProteoGenix; catalogue PX-TA2173; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Azirkitug Biosimilar – Anti-CKR-L1 mAb is a therapeutic antibody that has been developed as a biosimilar to the existing anti-CKR-L1 monoclonal antibody. This biosimilar has been created using advanced biotechnology techniques and is designed to have similar structure, activity, and application as the original anti-CKR-L1 mAb.
Azirkitug Biosimilar – Anti-CKR-L1 mAb is a monoclonal antibody, which means it is made up of identical copies of a single type of antibody. It is a large protein molecule, with a molecular weight of approximately 150 kDa. The antibody is composed of two heavy chains and two light chains, which are held together by disulfide bonds. These chains are made up of constant and variable regions, with the variable regions being responsible for binding to the target molecule, CKR-L1.
The primary activity of Azirkitug Biosimilar – Anti-CKR-L1 mAb is to bind to the CKR-L1 protein. CKR-L1, also known as C-X-C chemokine receptor type 5 (CXCR5), is a cell surface protein that is expressed on certain immune cells, including B cells and T cells. It is a chemokine receptor, which means it is involved in the movement and activation of immune cells.
By binding to CKR-L1, Azirkitug Biosimilar – Anti-CKR-L1 mAb blocks its activity, preventing the recruitment and activation of immune cells. This can be beneficial in certain diseases where the overactivation of immune cells is harmful, such as autoimmune diseases and inflammatory disorders.
Azirkitug Biosimilar – Anti-CKR-L1 mAb has potential applications in the treatment of various diseases. Some of the key therapeutic areas where this biosimilar can be used include:
Autoimmune diseases are conditions where the immune system mistakenly attacks healthy cells and tissues in the body. By targeting and blocking CKR-L1, Azirkitug Biosimilar – Anti-CKR-L1 mAb can help to reduce the activity of immune cells and prevent damage to healthy tissues. This can be beneficial in diseases such as rheumatoid arthritis, multiple sclerosis, and lupus.
Inflammatory disorders are conditions where there is excessive inflammation in the body, leading to tissue damage and dysfunction. By inhibiting CKR-L1, Azirkitug Biosimilar – Anti-CKR-L1 mAb can help to reduce the recruitment and activation of immune cells, thereby reducing inflammation. This can be useful in diseases such as asthma, psoriasis, and inflammatory bowel disease.
CKR-L1 is also known to play a role in the growth and spread of certain types of cancer. By targeting this protein, Azirkitug Biosimilar – Anti-CKR-L1 mAb can potentially inhibit the growth and metastasis of cancer cells. This makes it a promising candidate for the treatment of cancers such as lymphoma and leukemia.
Infectious diseases are caused by pathogens such as bacteria, viruses, and parasites. CKR-L1 is involved in the recruitment of immune cells to the site of infection, making it a potential target for therapy. By blocking CKR-L1, Azirkitug Biosimilar – Anti-CKR-L1 mAb can help to reduce the spread and severity of infectious diseases.
CKR-L1 is a promising therapeutic target due to its involvement in
ProteoGenix catalogue number PX-TA2173. For research use only.
Target: Azirkitug Biosimilar – Anti-CKR-L1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
